Topcon (7732) Q2 2025 earnings summary

Executive summary

• Net sales for Q2 FY2024 rose 1% YoY to ¥105.5B, but operating income fell 22% to ¥3.0B due to Positioning Business weakness and higher Eye Care investments.

• Net income attributable to owners plunged 90% YoY to ¥0.1B, and comprehensive income turned negative at ¥-3.7B.

• Full-year outlook revised downward: net sales now expected at ¥220.0B (+2% YoY), operating income at ¥12.0B (+7% YoY), reflecting challenges in IT Agriculture and delayed product launches.

• Eye Care Business remains on track for record sales and profit, while Positioning Business faces headwinds from the agricultural machinery market.

• Overseas sales accounted for 83.4% of consolidated sales, with North America and Europe contributing 37.2% and 26.4% respectively.

Financial highlights

• Gross profit for 1H FY2024 rose 2% YoY to ¥56.0B, with gross margin improving to 53.1%.

• Ordinary income dropped sharply by 89% YoY to ¥0.4B; net income declined 90% YoY to ¥0.1B.

• Operating income ratio decreased from 3.7% to 2.8% YoY.

• Basic earnings per share fell to ¥0.58 from ¥5.78 YoY.

• Net cash provided by operating activities increased to ¥5.2B from ¥3.3B YoY.

Outlook and guidance

• Full-year net sales forecast revised to ¥220.0B (down ¥10.0B from previous plan), operating income to ¥12.0B (down ¥6.0B).

• Ordinary profit projected at ¥8.0B (down 9.7% YoY), and profit attributable to owners at ¥4.5B (down 8.9% YoY).

• Positioning Business outlook lowered due to persistent weakness in IT Agriculture and delayed recovery.

• Eye Care Business guidance unchanged; expects record highs in both net sales and operating income.

• Dividend forecast maintained at ¥42 per share; payout ratio expected to rise to 98%.